100 related articles for article (PubMed ID: 3780438)
1. [Therapy and prognosis of malignant melanoma of the skin].
Braun-Falco O; Landthaler M; Hölzel D; Konz B; Schmoeckel C
Dtsch Med Wochenschr; 1986 Nov; 111(46):1750-6. PubMed ID: 3780438
[TBL] [Abstract][Full Text] [Related]
2. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb].
Garbe C; Guenther-Eymann K; Stadler R; Orfanos CE
Hautarzt; 1988 Apr; 39(4):205-12. PubMed ID: 3384660
[TBL] [Abstract][Full Text] [Related]
4. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
[TBL] [Abstract][Full Text] [Related]
6. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
7. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
9. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
11. Postsurgical adjuvant treatment of malignant melanoma patients by the thymic factor thymostimulin.
Azizi E; Brenner HJ; Shoham J
Arzneimittelforschung; 1984; 34(9):1043-7. PubMed ID: 6542371
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
13. Survival with regional and distant metastases from cutaneous malignant melanoma.
Roses DF; Karp NS; Oratz R; Dubin N; Harris MN; Speyer J; Boyd A; Golomb FM; Ransohoff J; Dugan M
Surg Gynecol Obstet; 1991 Apr; 172(4):262-8. PubMed ID: 2006449
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of patients with pathologic stage II cutaneous malignant melanoma.
Roses DF; Provet JA; Harris MN; Gumport SL; Dubin N
Ann Surg; 1985 Jan; 201(1):103-7. PubMed ID: 3966826
[TBL] [Abstract][Full Text] [Related]
15. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
16. Management of malignant melanoma.
Kroon BB; Nieweg OE
Ann Chir Gynaecol; 2000; 89(3):242-50. PubMed ID: 11079795
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
19. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
Korting HC; Strasser S; Konz B
Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
[TBL] [Abstract][Full Text] [Related]
20. [Surgical and adjuvant drug therapy in head and neck cutaneous melanoma].
Hauschild A; Lischner S; Christophers E
Laryngorhinootologie; 2000 Jul; 79(7):428-33. PubMed ID: 11005097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]